CA-LEVITASBIO
7.4.2022 15:17:04 CEST | Business Wire | Press release
LevitasBio, Inc. today unveiled the LeviCell™ EOS System, their next generation solution for cell separation and enrichment, featuring higher throughput and simultaneous targeted selection of viable cells. Utilizing field proven Levitation Technology, researchers can now effectively scale their experiments up to 16x and process up to 40 million cells per run. The LeviCell EOS System debuts, along with new LeviPrep and LeviSelect product lines for tissue dissociation and targeted cellular selection, at the 2022 American Association for Cancer Research General Meeting held April 8-13 in New Orleans, Louisiana.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220407005408/en/
Unprecedented Sample Throughput and Scalability
LevitasBio first revolutionized sample preparation in 2020 with the launch of the LeviCell System, which introduced researchers to a gentle, fast, and unbiased method to separate and enrich cells of interest via magnetic levitation. Less than two years later, LevitasBio has addressed researchers’ oft stated desire for scalability, both in the quantity of samples and cells that can be levitated and accessed. The new LeviCell EOS system increases sample throughput by four-fold and enables up to four LeviCell EOS modules to be interconnected and independently controlled, increasing total scalability by 16x. Researchers can now accelerate their discoveries with unprecedented sample processing power and insights.
A New Era in Sample Processing
The LeviCell EOS system introduces several new features that enhance unbiased sample processing to optimize the study of natural biology. First is an embedded thermal control system, which allow users to select from a range of pre-defined temperatures, ensuring samples are processed at ideal temperatures to maintain cellular states.
Additionally, an advanced, fully reticulated imaging system enables powerful, real-time sample characterization analytics during processing. Important insights such as fractionation, cell counts, viability assessment, and quality measurements, can be reviewed real-time, empowering researchers to make informed decisions on how to best utilize their enriched samples in downstream studies.
Finally, the LeviCell EOS system delivers unprecedented flexibility with a modular and interchangeable EOS Magnetic Core. A growing family of selectable core modules will enable a broad range of specifically optimized applications on a single platform.
“We are changing the landscape of how researchers conduct their experiments,” says Martin Pieprzyk, CEO of LevitasBio. “The new LeviCell EOS system paves the way for fully integrated approaches to sample processing and accurate characterization at scaled throughputs. This marks a profound shift in how scientists work with their samples.”
For more information, visit http://www.levitasbio.com/eos . For collaborations and business development, contact Paul Steinberg at steinberg@levitasbio.com .
About LevitasBio
LevitasBio has pioneered a new and powerful method of cellular enrichment and analysis. Utilizing proprietary Levitation Technology, our LeviCell platform can accurately and gently detect, quantify, enrich, and test cells. Our unbiased, label-free method can detect cell type and state with minimal time and handling, and has been adopted across a broad range of critical applications, including single cell multi-omics, CRISPR, and cell line development.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005408/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom